N-(2-diethylaminoethyl)benzene-1,4-diamine | 38519-13-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2-diethylaminoethyl)benzene-1,4-diamine
• 英文别名: N¹-(2-(diethylamino)ethyl)benzene-1,4-diamine；4-(β-Diethylaminoethylamino)-anilin；N-(2-diethylamino-ethyl)-p-phenylenediamine；N-(2-Diaethylamino-aethyl)-p-phenylendiamin；N-(β-Diaethylamino-aethyl)-p-phenylendiamin；N-[2-(Diethylamino)ethyl]-1,4-benzenediamine；1,4-Benzenediamine, N1-[2-(diethylamino)ethyl]-；4-N-[2-(diethylamino)ethyl]benzene-1,4-diamine
• CAS: 38519-13-0
• 化学式: C₁₂H₂₁N₃
• 分子量: 207.319
• InChiKey: VGDBSAICXDCFAW-UHFFFAOYSA-N

物化性质

• 沸点：
  156 °C(Press: 0.02 Torr)
• 密度：
  1.031±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氯苯基氰胺 、 N-(2-diethylaminoethyl)benzene-1,4-diamine 在 盐酸 、 乙醇 作用下， 生成 N-(4-chloro-phenyl)-N'-[4-(2-diethylamino-ethylamino)-phenyl]-guanidine
  参考文献：
  名称：

  169.合成抗疟药。第十九部分。二烷基氨基烷基氨基二苯基胍

  摘要：

  DOI：

  10.1039/jr9470000914
• 作为产物：
  描述：

  2-[(4-硝基苯基)氨基]乙醇 在 palladium on activated charcoal TEA 、 一水合肼 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 反应 70.5h， 生成 N-(2-diethylaminoethyl)benzene-1,4-diamine
  参考文献：
  名称：

  Structure−Activity Relationship of Quinoline Derivatives as Potent and Selective α_2C-Adrenoceptor Antagonists

  摘要：

  Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human alpha(2)-adrenoceptor subtypes (alpha(2A), alpha(2B), and alpha(2C.)). A number of compounds with good antagonist potencies against the alpha(2C)-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl) phenylamino] quinolin- 3- yl} methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the alpha(2C)-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the alpha(2C)-adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.

  DOI：

  10.1021/jm060262x

文献信息

• [DE] NEUE AMID-VERBINDUNGEN MIT MCH-ANTAGONISTISCHER WIRKUNG UND DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL<br/>[EN] NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES DE TYPE AMIDE EXERÇANT UNE ACTION ANTAGONISTE SUR L'HORMONE MCH, ET MEDICAMENTS CONTENANT CES COMPOSES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004039764A1

  公开（公告）日：2004-05-13

  Die vorliegende Erfindung betrifft Amid-Verbindungen der allgemeinen Formel (I), in der die Gruppen und Reste A, B, b, W, X, Y, Z, R1, R2 und R3 die in Anspruch 1 angegebenen Bedeutungen aufweisen. Ferner betrifft die Erfindung Arzneimittel enthaltend mindestens ein erfindungsgemässes Amid. Auf Grund der MCH-Rezeptor antagonistischen Aktivität eignen sich die erfindungsgemässen Arzneimittel zur Behandlung von metabolischen Störungen und/oder Essstörungen, insbesondere von Obesitas, Bulimie, Anorexie, Hyperphagia und Diabetes.

  该发明涉及通式（I）的酰胺化合物，其中基团和残基A、B、b、W、X、Y、Z、R1、R2和R3具有权利要求1中所述的含义。此外，该发明涉及含有至少一种根据本发明的酰胺的药物。由于MCH受体拮抗活性，根据本发明的药物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。
• [EN] SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE<br/>[FR] QUINONES BICYCLIQUES ET TÉTRACYCLIQUES SUBSTITUÉES ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2020181207A1

  公开（公告）日：2020-09-10

  This invention is in the field of medicinal chemistry. In particular, the invention relates to small molecule compounds having bicyclic and tetracyclic quinone scaffolds which have antiproliferative activities through, for example, induction of reactive oxygen species. The invention further processes for preparing, and methods for using these compounds to treat cancer (e.g., pancreatic cancer, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer).

  这项发明属于药物化学领域。具体来说，该发明涉及具有双环和四环喹诺骨架的小分子化合物，通过诱导活性氧化物种等方式具有抗增殖活性。该发明还涉及制备这些化合物的方法，以及使用这些化合物治疗癌症（例如胰腺癌、白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）的方法。
• Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040152742A1

  公开（公告）日：2004-08-05

  The present invention relates to amide compounds of general formula I 1 wherein the groups and residues A, B, b, W, X, Y, Z, R 1 , R 2 and R 3 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I1的酰胺化合物，其中基团和残基A、B、b、W、X、Y、Z、R1、R2和R3具有权利要求1中给出的含义。此外，本发明涉及至少含有本发明中一种酰胺的药物组合物。鉴于MCH受体拮抗活性，本发明中的药物组合物适用于治疗代谢性疾病和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。
• 1-(4-substituted phenyl)-1H-imidazoles as cardiovascular agents
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP0306440A2

  公开（公告）日：1989-03-08

  Novel 1-(4-substituted phenyl)-1H-imidazoles and their use as antiarrhythmic, anti-hypertensive and anti-ischemic agents is described. Pharmaceutical formulations containing such compounds are also discussed.

  介绍了新型 1-（4-取代苯基）-1H-咪唑类化合物及其作为抗心律失常、抗高血压和抗缺血药物的用途。还讨论了含有此类化合物的药物制剂。
• Basic ethers of 2-anilinobenzothiazoles and 2-anilinobenzoxazoles as potential antidepressants
  作者：C. J. Sharpe、P. J. Palmer、D. E. Evans、G. R. Brown、Gillian King、R. S. Shadbolt、R. B. Trigg、R. J. Ward、A. Ashford、Janet W. Ross

  DOI：10.1021/jm00275a022

  日期：1972.5